RECTAL ADENOCARCINOMA

This study is for people with rectal cancer that didn't fully go away after standard chemotherapy and radiation. Instead of moving straight to surgery, doctors will give extra internal radiation (brachytherapy) directly to the remaining tumor. The goal is to see if this can compl…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation, chemotherapy, and a targeted therapy) can improve outcomes for people with locally advanced rectal cancer. About 104 participants will receive the standard…

This study is for people with a certain type of advanced rectal cancer called HER2-positive. Researchers are testing whether adding two targeted drugs, tucatinib and trastuzumab, to standard chemotherapy can shrink tumors more effectively before surgery or radiation. About 37 adu…

This early-phase study tests whether MRI-guided radiation therapy can safely treat rectal cancer while allowing patients to keep their rectum. About 22 adults with stage I to III rectal cancer will receive tailored radiation and chemotherapy. The main goal is to check for serious…

This study tests a personalized treatment plan for people with rectal cancer that hasn't spread. The goal is to avoid removing the rectum when possible, using a combination of scans and genetic tests to guide decisions. If organ removal is needed, the approach uses less invasive …

This study is testing whether people with stage II or III rectal cancer can safely avoid surgery by using chemotherapy followed by close monitoring (active surveillance) instead of immediate surgery. The goal is to see if the organ can be preserved without the cancer coming back.…

This study tests whether adding the targeted drugs MK-1084 and cetuximab to standard chemotherapy (mFOLFOX6) helps people with a specific genetic mutation (KRAS G12C) in advanced colorectal cancer live longer without the cancer growing. About 477 participants will be randomly ass…

This study is for people with rectal cancer whose tumors completely disappear after initial chemotherapy and radiation. Instead of routine surgery, doctors will closely monitor them to see if the cancer stays away. The goal is to safely avoid major surgery and preserve the rectum…

This study tests whether adding the antibiotic metronidazole to standard cancer therapy can reduce harmful bacteria in the gut of people with rectal cancer. About 60 adults with advanced rectal cancer will receive either standard treatment plus metronidazole or standard treatment…

This study tests whether a drug called TSR-042, followed by standard chemotherapy and radiation, can shrink or eliminate advanced solid tumors that have a specific genetic flaw (mismatch repair deficiency). About 200 adults with locally advanced tumors that haven't spread will re…

This early-phase study tests whether a short course of radiation followed by chemotherapy can shrink tumors enough to avoid surgery in people with stage II-III rectal cancer. The goal is to preserve the rectum and improve quality of life. About 25 adults with locally advanced rec…

This study is testing a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with a specific type of advanced colorectal cancer that has spread (HER-2 positive). The goal is to see how well this drug combo shrinks tumo…

This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment in 50 adults with stage II …

This study follows 100 adults with rectal cancer to see how bowel function changes over 2 years after surgery. Participants may receive different treatments before surgery, and the goal is to learn which factors lead to better or worse bowel outcomes. The findings could help doct…

This study follows 430 people with stage I-IV rectal cancer to see how surgery affects their daily life and well-being. Participants fill out questionnaires about their health and preferences. No new treatments are given—the goal is simply to learn more about what life is like af…